BCAL Diagnostics Lands Medtech Veteran CEO to Drive Cancer Test Commercialisation
BCAL Diagnostics names Anne-Louise Arnett as Chief Executive Officer
BCAL Diagnostics (ASX: BDX) has appointed Anne-Louise (Annie) Arnett as Chief Executive Officer, effective 1 June 2026, to accelerate the company’s commercial roadmap. The hire brings more than 25 years of medical technology experience to the role at a time when BCAL is preparing to bring multiple products to market both domestically and internationally. With a track record spanning diagnostics, capital equipment and regulated product portfolios, Arnett’s appointment signals a deliberate shift toward commercial execution as the company matures.
When big ASX news breaks, our subscribers know first
A commercial operator built for BCAL’s next chapter
Arnett’s career trajectory maps closely to the operational challenges BCAL faces as it scales: building commercial infrastructure, entering regulated markets, and launching complex diagnostic products across multiple geographies.
Her three most directly relevant roles are:
- General Manager ANZ, Arthrex: Built the Australian and New Zealand commercial business following a transition from a distributor model to direct market operations, growing the business from inception to achieve high double-digit growth across five years.
- Vice President and General Manager ANZ, Hologic: Led a portfolio spanning Capital Diagnostic Imaging, Women’s Health Surgery and Diagnostics across three business units, driving revenue growth and introducing new diagnostic testing into the Australian and New Zealand market. Her work in cancer sector advocacy and government relations including engagement with screening program policy is directly relevant to BCAL’s operating environment.
- Senior global marketing roles, Stryker: Led new product development and the global launch of multiple products across the surgical business unit, integrating four acquisitions and directing commercial strategy across the US, EU and APAC markets.
Arnett holds a Master of Business (Marketing) from the University of Technology Sydney and a Bachelor of Science from the Australian National University. She is also a 2025 graduate of the Australian Institute of Company Directors (AICD).
Her regulatory environment knowledge and international market entry experience are directly aligned to the demands of BCAL’s pipeline execution across both Australian and international markets.
Executive Chair Jayne Shaw
“Annie is the right CEO to take BCAL into its next chapter. We have built a genuinely differentiated portfolio of early cancer detection products and the opportunity in front of us, both here in Australia and internationally is substantial. Annie has spent her career doing exactly what we need: taking innovative medical technology to market, building the commercial infrastructure to support it, and scaling organisations to meet that growth. Her deep familiarity with diagnostic and medical technology products, regulatory environments and international market entry will be invaluable as we execute our pipeline.”
In her own words
Arnett has articulated a clear commercial mandate for her incoming tenure.
Incoming CEO Anne-Louise Arnett
“I am excited to be joining BCAL and working with the Board and team on the compelling product pipeline, from BREASTESTplus through to the Multi Cancer Early Detection (MCED) platform. Early cancer detection is one of the most important areas in healthcare, and BCAL has built something genuinely special and meaningful to patients. I look forward to bringing my commercial and organisational experience to the opportunities, both domestically and across international markets to realise the potential this technology can bring for BCAL and its shareholders.”
Leadership structure evolving as BCAL matures
Two concurrent leadership changes accompany the CEO appointment, each designed to preserve continuity while moving the organisation toward a more conventional governance structure.
Outgoing CEO Shane Ryan transitions to the role of Director Clinical Affairs Breast Cancer, effective 1 June 2026. His retention is a deliberate continuity mechanism, keeping the scientific and clinical expertise behind BREASTESTplus within the business while commercial leadership passes to Arnett.
Jayne Shaw, who has served as Executive Chair since BCAL’s ASX listing, will transition to Non-Executive Chair, effective 1 July 2026. The shift reflects the natural evolution of BCAL’s governance structure as the company matures. Shaw will remain actively engaged with the company and the board.
In summary, the new leadership structure is:
- Annie Arnett → CEO, effective 1 June 2026
- Shane Ryan → Director Clinical Affairs Breast Cancer (retained)
- Jayne Shaw → Non-Executive Chair, effective 1 July 2026
The next major ASX story will hit our subscribers first
What this means for BCAL’s pipeline and investors
BCAL is an early-stage Australian diagnostics company that has already launched its first product, BREASTESTplus, a non-invasive blood test used alongside mammography to improve screening and diagnostic outcomes for breast health in women with dense breasts. Beyond this, the company holds an exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of the Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.
The appointment of a commercially focused CEO at this stage reflects a transition from product development toward market execution and geographic expansion. A commercially experienced operator with Arnett’s specific background in regulatory environments, government relations, and international market entry is well-suited to progressing this pipeline toward revenue.
Arnett’s remuneration structure, disclosed in accordance with ASX Listing Rule 3.16.4, provides a further alignment signal for investors:
| Remuneration Component | Detail | Notes | Alignment Signal |
|---|---|---|---|
| Base Salary | $403,650 | Plus statutory superannuation | Market-rate for senior medtech executive |
| Short Term Incentive | Up to 50% of base salary | Tied to agreed milestones | Performance-linked |
| Long Term Incentive | 2 million Performance Rights (ASX: BDX) | Vest on 6 months’ service; additional rights FY2027–FY2029 to be agreed | Shareholder-aligned |
| Termination Period | 3 months | Standard | — |
The 2 million Performance Rights each convert into one ASX: BDX share on a 1:1 basis, directly aligning Arnett’s long-term incentives with shareholder value creation. With a specialist commercial operator now in place, BCAL enters its next phase focused on domestic scale and international expansion across its cancer detection portfolio.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare and biotech news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market and click the “Free Alerts” button at StockWire X to receive the next market-moving announcement the moment it drops.